Skip to main content
. 2023 Nov 22;13:1235786. doi: 10.3389/fonc.2023.1235786

Table 3.

Different endpoints to progression-free survival.

TO (n = 64) TA (n = 32) p
Local lesion progression 20 (31.3%) 8 (25.0%)
Intrahepatic metastasis 30 (46.9%) 10 (31.3%)
Extrahepatic metastasis 8 (12.5%) 4 (12.4%)
death 6 (9.3%) 10 (31.3%) 0.054

Data are presented as n (%),

TO, TACE only; TA, TACE combined with anlotinib; TACE, transarterial chemoembolization.